Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Two EUMelaReg poster presentations at World Congress of Melanoma and EADO Congress in Athens

We are proud to announce that two EUMelaReg studies were accepted for poster presentation at the 11th World Congress of Melanoma and 21st EADO Congress, which will be held on April 3-5, 2025 in Athens.

The first study, “Single agent anti-PD-1 versus combined BRAF and MEK inhibitors upfront in metastatic or unresectable BRAF V600 mutated melanoma - A EUMelaReg real-world evidence study”, examines the impact of baseline demographics on treatment efficacy in real-world settings. While anti-PD-1 checkpoint inhibitors have shown significant efficacy and durable benefit in clinical trials in patients with metastatic melanoma by reducing the risk of disease progression and death compared to previous standard therapy, there is still limited evidence on how baseline demographics influence treatment efficacy in practice. The study aims to provide further insights into this.

The second EUMelaReg poster wich will be presented is a registry based cohort study with the title ”EURO-NMSC: Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – A Registry Based Cohort Study”. The EURO-NMSC initiative of the EUMelaReg consortium is aiming at implementing a comprehensive platform for registration and evaluation of advanced non-melanoma skin cancer (NMSC) across Europe. We have created a foundation data model, that implements both established and newly developed standards for describing and quantifying the burden of disease for advanced NMSC. In accordance with EADO and others, the EURO-NMSC initiative will hopefully help to improve treatment, care and outcome for patients with locally advanced NMSC.